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Sir,
We thank Drs Finsterer and Zarrouk-Mahjoub for their interest
in our recent paper describing a family with two siblings af-
fected by a mitochondrial disorder caused by a rare mitochon-
drial DNA variant m.8969G>A [1]. Their letter provides us
with the opportunity to make specific points clearer.
The authors wonder why our patients’ spectroscopy was
normal while CSF was elevated, and pay attention to this
discrepancy. We agree that it is puzzling when cerebrospinal
fluid (CSF) lactate was increased whereas spectroscopy (1H-
MRS) did not show a lactate peak although theywere taken on
the same day. Spectroscopy is a sensitive tool in diagnosis of
brain lactate, if the site of interrogation is correct, which may
be difficult when brain MRI is normal [2, 3]. Mitochondrial
disease usually affects only specific regions of the brain, and
in our case with normal MRI, the spectroscopy was investi-
gated from the thalamus. Multi-region spectroscopy might
have better detected the affected area in the brain [4].
Additionally, they ask for more detailed clinical data of the
patients and their family members, which we are happy to
provide.
No family members of these siblings had clinical signs of a
mitochondrial disorder: parents and the other two siblings
were healthy, the maternal grandmother had had migraine,
but was otherwise healthy, as was her sister. No family mem-
bers underwent histological or biochemical examinations. The
threshold for manifesting disease is unknown for this particu-
lar variant, but healthy members in our family had much lower
heteroplasmy levels in blood (< 1–18%) than the asymptom-
atic mother (49%) described by Wen et al. [5]. Unfortunately,
we had no opportunity to determine heteroplasmy of other
tissues than described in the table, but heteroplasmy has been
at a high level in all affected patients in all tissues studied
(blood 61–96%, fibroblasts 85–96%, muscle 88–95%, kidney
89% and urine 79%) [1].
None of the family had seizures. The affected brother had
asymptomatic centrotemporal spikes during sleep, while oth-
erwise normal EEG. Both affected siblings had been exam-
ined and followed up by an ophthalmologist. They had no
optic atrophy nor findings typical for Leber’s hereditary optic
neuropathy, only mild tortuosity of the retinal vessels without
clinical symptoms. Visually evoked potentials had not been
examined. No medication had been used, but rehabilitation
therapies and dietary measures were ongoing.
Lastly, we would like to comment that Finsterer and
Zurrocuk-Mahjoub calculated a modified Yarham score, the
score which was established specifically for MT-tRNA muta-
tions [6], to the MT-ATP6 m.8969G>A variant to be 11, indi-
cating the variant as ‘probably pathogenic’. We consider that
the following facts support the pathogenic role of this variant:
more than one previous independent reports, the base is evo-
lutionarily conserved, the variant is heteroplasmic, the variant
segregates with the disease in the pedigree, and ATP produc-
tion was decreased in our patient. Furthermore, studies in
yeast [5] confirm the pathogenicity of this variant.
We hope that with these additions and clarifications, our
report would benefit both to clinicians and scientist in the
fascinating field of mitochondrial diseases.
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